New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
08:18 EDTSGMOSangamo price target raised to $27 from $22 at Wedbush
Wedbush raised its price target for Sangamo BioSciences to $27 saying the phase 1 results published in the New England Journal of Medicine suggest that the company's ZFN approach to treating HIV has broad acceptance in the medical and scientific communities. The firm reiterats an Outperform rating on the stock.
News For SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:14 EDTSGMOSangamo's XFP Thereapeutic HIV candidate shows positive trial results
Subscribe for More Information
February 19, 2015
18:25 EDTSGMOPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use